89bio (ETNB) Financials

$6.79 +0.17 (+2.63%)

As of 01:37 PM Eastern

Annual Income Statements for 89bio

This table shows 89bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-102	-142	-367
Consolidated Net Income / (Loss)	-102	-142	-367
Net Income / (Loss) Continuing Operations	-102	-142	-367
Total Pre-Tax Income	-102	-138	-366
Total Operating Income	-102	-151	-385
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	102	151	385
Selling, General & Admin Expense	21	29	40
Research & Development Expense	81	122	345
Total Other Income / (Expense), net	0.24	13	18
Interest Expense	1.92	4.79	5.29
Other Income / (Expense), net	2.16	18	24
Income Tax Expense	0.02	3.87	0.69
Basic Earnings per Share	($2.93)	($2.00)	($3.51)
Weighted Average Basic Shares Outstanding	34.81M	71.17M	104.71M
Diluted Earnings per Share	($2.93)	($2.00)	($3.51)
Weighted Average Diluted Shares Outstanding	34.81M	71.17M	104.71M
Weighted Average Basic & Diluted Shares Outstanding	52.23M	93.50M	145.98M

This table shows 89bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-27	-25	-29	-39	-35	-40	-52	-48	-147	-120
Consolidated Net Income / (Loss)	-27	-25	-29	-38	-35	-40	-52	-48	-149	-118
Net Income / (Loss) Continuing Operations	-27	-25	-29	-38	-35	-40	-52	-48	-149	-118
Total Pre-Tax Income	-27	-25	-29	-38	-35	-36	-52	-48	-149	-118
Total Operating Income	-27	-25	-29	-42	-39	-41	-57	-53	-152	-122
Total Operating Expenses	27	25	29	42	39	41	57	53	152	122
Selling, General & Admin Expense	4.84	6.30	6.22	7.21	7.93	7.61	9.85	8.57	10	11
Research & Development Expense	22	19	22	35	31	34	47	45	141	111
Total Other Income / (Expense), net	0.24	0.78	-0.31	3.74	4.62	4.84	5.69	5.60	3.07	3.91
Interest Expense	0.54	0.55	2.08	0.89	0.96	0.87	0.86	0.87	2.36	1.19
Other Income / (Expense), net	0.77	1.32	1.76	4.63	5.58	5.70	6.56	6.47	5.43	5.10
Income Tax Expense	0.00	0.02	0.00	0.00	0.00	3.87	0.10	0.13	0.20	0.26
Basic Earnings per Share	($0.57)	$0.13	($0.54)	($0.52)	($0.45)	($0.49)	($0.54)	($0.48)	($1.39)	($1.10)
Weighted Average Basic Shares Outstanding	47.25M	34.81M	53.17M	74.13M	76.34M	71.17M	95.85M	99.83M	107.08M	104.71M
Diluted Earnings per Share	($0.57)	$0.13	($0.54)	($0.52)	($0.45)	($0.49)	($0.54)	($0.48)	($1.39)	($1.10)
Weighted Average Diluted Shares Outstanding	47.25M	34.81M	53.17M	74.13M	76.34M	71.17M	95.85M	99.83M	107.08M	104.71M
Weighted Average Basic & Diluted Shares Outstanding	46.54M	52.23M	72.87M	75.48M	75.64M	93.50M	98.38M	105.91M	106.13M	145.98M

This table details how cash moves in and out of 89bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	2.80	261	-190
Net Cash From Operating Activities	-81	-129	-368
Net Cash From Continuing Operating Activities	-81	-129	-368
Net Income / (Loss) Continuing Operations	-102	-142	-367
Consolidated Net Income / (Loss)	-102	-142	-367
Depreciation Expense	0.07	0.05	0.04
Amortization Expense	-0.22	-5.37	-9.14
Non-Cash Adjustments To Reconcile Net Income	11	18	23
Changes in Operating Assets and Liabilities, net	11	0.78	-15
Net Cash From Investing Activities	-34	-123	-41
Net Cash From Continuing Investing Activities	-34	-123	-41
Purchase of Property, Plant & Equipment	-0.01	-0.00	-0.02
Purchase of Investments	-153	-341	-376
Sale and/or Maturity of Investments	119	218	335
Net Cash From Financing Activities	118	513	219
Net Cash From Continuing Financing Activities	118	513	219
Repayment of Debt	0.00	-21	0.00
Repurchase of Common Equity	0.00	0.00	-0.25
Issuance of Debt	0.00	24	9.35
Issuance of Common Equity	117	496	158
Other Financing Activities, net	1.09	14	52
Cash Interest Paid	1.08	2.59	3.14

This table details how cash moves in and out of 89bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	12	-17	296	-105	6.49	64	-99	-5.36	-121	35
Net Cash From Operating Activities	-15	-27	-30	-34	-30	-34	-40	-61	-145	-122
Net Cash From Continuing Operating Activities	-15	-27	-30	-34	-30	-34	-40	-61	-145	-122
Net Income / (Loss) Continuing Operations	-27	-25	-29	-38	-35	-40	-52	-48	-149	-118
Consolidated Net Income / (Loss)	-27	-25	-29	-38	-35	-40	-52	-48	-149	-118
Depreciation Expense	0.02	0.02	0.01	0.01	0.01	0.02	0.01	0.01	0.01	0.01
Amortization Expense	-0.24	-0.26	-0.82	-0.91	-1.87	-1.77	-2.66	-2.42	-2.31	-1.76
Non-Cash Adjustments To Reconcile Net Income	2.76	2.43	4.80	4.18	4.42	4.14	5.17	5.46	6.83	5.42
Changes in Operating Assets and Liabilities, net	9.45	-4.68	-5.24	0.67	1.80	3.55	9.44	-16	-0.82	-6.90
Net Cash From Investing Activities	-42	-11	4.11	-102	38	-64	-80	28	-8.64	20
Net Cash From Continuing Investing Activities	-42	-11	4.11	-102	38	-64	-80	28	-8.64	20
Purchase of Property, Plant & Equipment	-	-0.00	0.00	-	-	-0.00	0.00	-	-	-0.02
Purchase of Investments	-69	-43	-34	-147	-36	-124	-152	-78	-83	-63
Sale and/or Maturity of Investments	27	32	38	45	75	61	72	106	74	83
Net Cash From Financing Activities	69	21	322	31	-1.48	162	21	28	33	136
Net Cash From Continuing Financing Activities	69	21	322	31	-1.48	162	21	28	33	136
Repurchase of Common Equity	-	-	0.00	-	-	-	-0.25	0.14	-	-0.14
Issuance of Common Equity	69	20	310	24	-	162	21	0.06	-	136
Other Financing Activities, net	-	1.16	8.27	7.14	-1.48	0.02	0.11	28	24	0.08
Cash Interest Paid	0.30	0.37	0.54	0.66	0.72	0.68	0.68	0.69	0.69	1.08

This table presents 89bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	197	596	479
Total Current Assets	196	594	476
Cash & Equivalents	55	316	126
Short-Term Investments	133	263	314
Inventories, net	0.36	2.29	1.57
Prepaid Expenses	7.92	15	36
Plant, Property, & Equipment, net	0.09	0.05	0.02
Total Noncurrent Assets	0.29	0.40	0.64
Other Noncurrent Operating Assets	0.29	0.40	0.64
Total Liabilities & Shareholders' Equity	197	596	479
Total Liabilities	45	60	78
Total Current Liabilities	25	30	36
Accounts Payable	13	8.59	15
Accrued Expenses	12	21	20
Other Current Liabilities	0.17	0.50	0.73
Total Noncurrent Liabilities	20	30	42
Long-Term Debt	20	25	36
Other Noncurrent Operating Liabilities	0.19	5.56	6.04
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	152	536	401
Total Preferred & Common Equity	152	536	401
Preferred Stock	0.00	0.00	0.00
Total Common Equity	152	536	401
Common Stock	467	994	1,225
Retained Earnings	-315	-457	-825
Accumulated Other Comprehensive Income / (Loss)	-0.35	0.19	0.56

This table presents 89bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	201	494	493	460	577	582	458
Total Current Assets	200	494	492	460	575	580	456
Cash & Equivalents	72	351	245	252	218	212	91
Restricted Cash	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Short-Term Investments	121	130	233	196	345	319	332
Inventories, net	0.40	-	0.28	0.24	2.12	1.94	1.76
Prepaid Expenses	6.51	13	14	11	12	48	32
Plant, Property, & Equipment, net	0.11	0.08	0.07	0.06	0.04	0.03	0.02
Total Noncurrent Assets	0.22	0.61	0.29	0.29	0.39	0.32	0.31
Other Noncurrent Operating Assets	0.22	0.61	0.29	0.29	0.39	0.32	0.31
Total Liabilities & Shareholders' Equity	201	494	493	460	577	582	458
Total Liabilities	48	48	51	50	67	67	80
Total Current Liabilities	34	24	26	25	38	42	39
Accounts Payable	14	17	11	11	15	17	19
Accrued Expenses	13	7.12	15	14	20	19	19
Other Current Liabilities	0.17	0.17	0.17	0.18	0.70	0.76	0.74
Total Noncurrent Liabilities	14	24	25	25	29	26	41
Long-Term Debt	13	24	24	25	23	20	36
Other Noncurrent Operating Liabilities	0.62	0.14	0.10	0.05	5.48	5.21	5.52
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	153	446	442	410	511	515	378
Total Preferred & Common Equity	153	446	442	410	511	515	378
Total Common Equity	153	446	442	410	511	515	378
Common Stock	444	790	825	828	1,020	1,073	1,083
Retained Earnings	-291	-344	-382	-417	-509	-557	-706
Accumulated Other Comprehensive Income / (Loss)	-0.44	-0.24	-0.59	-0.55	-0.52	-0.68	1.27

This table displays calculated financial ratios and metrics derived from 89bio's official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-13.86%	-38.52%	-166.63%
EBIT Growth	-11.71%	-33.41%	-170.43%
NOPAT Growth	-13.94%	-47.88%	-154.40%
Net Income Growth	-13.21%	-39.37%	-158.16%
EPS Growth	34.60%	31.74%	-75.50%
Operating Cash Flow Growth	-5.61%	-59.31%	-184.72%
Free Cash Flow Firm Growth	-3.88%	-70.51%	-172.14%
Invested Capital Growth	-184.08%	-10.12%	80.67%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	1.05%	-10.30%	-28.19%
EBIT Q/Q Growth	1.69%	-9.39%	-29.10%
NOPAT Q/Q Growth	0.85%	-11.71%	-26.59%
Net Income Q/Q Growth	1.63%	-12.35%	-27.03%
EPS Q/Q Growth	32.80%	-44.93%	-21.03%
Operating Cash Flow Q/Q Growth	1.39%	-5.90%	-31.11%
Free Cash Flow Firm Q/Q Growth	-1.53%	-1.73%	-31.28%
Invested Capital Q/Q Growth	23.67%	-32.03%	66.09%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.02%	102.80%	100.19%
Interest Burden Percent	101.92%	103.59%	101.47%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-73.46%	-41.33%	-78.34%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-73.46%	-41.33%	-78.34%
Return on Equity Simple (ROE_SIMPLE)	-67.20%	-26.51%	-91.59%
Net Operating Profit after Tax (NOPAT)	-72	-106	-269
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-20.33%	-10.07%	-20.42%
Return On Investment Capital (ROIC_SIMPLE)	-41.61%	-18.86%	-61.68%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-100	-134	-361
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-100	-139	-370
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	3.90	1.58	2.07
Price to Tangible Book Value (P/TBV)	3.90	1.58	2.07
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.13	0.05	0.09
Long-Term Debt to Equity	0.13	0.05	0.09
Financial Leverage	-1.08	-1.05	-1.02
Leverage Ratio	1.29	1.15	1.15
Compound Leverage Factor	1.32	1.19	1.16
Debt to Total Capital	11.74%	4.42%	8.19%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	11.74%	4.42%	8.19%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	88.26%	95.58%	91.81%
Debt to EBITDA	-0.20	-0.18	-0.10
Net Debt to EBITDA	1.68	3.99	1.09
Long-Term Debt to EBITDA	-0.20	-0.18	-0.10
Debt to NOPAT	-0.28	-0.23	-0.13
Net Debt to NOPAT	2.35	5.23	1.50
Long-Term Debt to NOPAT	-0.28	-0.23	-0.13
Altman Z-Score	5.03	7.78	2.60
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.97	20.04	13.19
Quick Ratio	7.64	19.55	12.18
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-61	-104	-284
Operating Cash Flow to CapEx	-1,158,428.57%	-3,229,650.00%	-2,452,153.33%
Free Cash Flow to Firm to Interest Expense	-31.80	-21.74	-53.61
Operating Cash Flow to Interest Expense	-42.19	-26.95	-69.53
Operating Cash Flow Less CapEx to Interest Expense	-42.19	-26.95	-69.53
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-16	-18	-3.43
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-10	-1.63	14
Enterprise Value (EV)	424	291	426
Market Capitalization	592	845	830
Book Value per Share	$3.26	$7.09	$3.78
Tangible Book Value per Share	$3.26	$7.09	$3.78
Total Capital	172	561	437
Total Debt	20	25	36
Total Long-Term Debt	20	25	36
Net Debt	-168	-554	-404
Capital Expenditures (CapEx)	0.01	0.00	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-17	-15	0.37
Debt-free Net Working Capital (DFNWC)	171	564	440
Net Working Capital (NWC)	171	564	440
Net Nonoperating Expense (NNE)	30	36	98
Net Nonoperating Obligations (NNO)	-168	-554	-404
Total Depreciation and Amortization (D&A)	-0.15	-5.32	-9.10
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.93)	($2.00)	($3.51)
Adjusted Weighted Average Basic Shares Outstanding	34.81M	71.17M	104.71M
Adjusted Diluted Earnings per Share	($2.93)	($2.00)	($3.51)
Adjusted Weighted Average Diluted Shares Outstanding	34.81M	71.17M	104.71M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	52.23M	93.50M	145.98M
Normalized Net Operating Profit after Tax (NOPAT)	-72	-106	-269
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-52.07	-27.85	-68.26
NOPAT to Interest Expense	-37.24	-22.08	-50.90
EBIT Less CapEx to Interest Expense	-52.08	-27.85	-68.26
NOPAT Less CapEx to Interest Expense	-37.24	-22.08	-50.90
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-0.07%

This table displays calculated financial ratios and metrics derived from 89bio's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	4.98%	4.21%	-10.52%	-56.63%	-34.50%	-53.39%	-93.60%	-28.56%	-317.69%	-218.52%
EBIT Growth	7.28%	6.68%	-6.38%	-52.31%	-28.54%	-47.67%	-89.53%	-25.24%	-333.89%	-229.29%
NOPAT Growth	4.15%	3.35%	-13.61%	-70.30%	-45.50%	-62.47%	-100.80%	-26.84%	-286.17%	-196.09%
Net Income Growth	5.38%	6.41%	-12.79%	-53.24%	-29.55%	-63.54%	-79.22%	-24.95%	-329.30%	-194.16%
EPS Growth	59.57%	110.00%	57.14%	57.72%	21.05%	-476.92%	0.00%	7.69%	-208.89%	-124.49%
Operating Cash Flow Growth	-10.15%	4.05%	-23.58%	-132.20%	-104.93%	-26.56%	-32.03%	-77.56%	-378.77%	-254.53%
Free Cash Flow Firm Growth	56.04%	49.26%	-0.07%	-326.32%	-407.95%	-272.89%	-82.78%	-0.02%	-211.39%	-266.53%
Invested Capital Growth	-131.13%	-184.08%	-175.11%	70.91%	36.34%	-10.12%	-149.90%	175.12%	24.74%	80.67%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-8.04%	8.31%	-13.51%	-39.29%	7.22%	-4.56%	-44.38%	7.50%	-201.43%	20.26%
EBIT Q/Q Growth	-6.69%	8.48%	-11.31%	-40.13%	9.95%	-5.14%	-42.87%	7.41%	-211.96%	20.20%
NOPAT Q/Q Growth	-9.31%	6.21%	-12.47%	-47.70%	6.61%	-4.73%	-39.00%	6.71%	-184.34%	19.70%
Net Income Q/Q Growth	-6.99%	8.22%	-17.21%	-33.14%	9.55%	-15.87%	-28.45%	7.18%	-210.76%	20.61%
EPS Q/Q Growth	53.66%	122.81%	-515.38%	3.70%	13.46%	-8.89%	-10.20%	11.11%	-189.58%	20.86%
Operating Cash Flow Q/Q Growth	0.13%	-82.90%	-11.03%	-14.50%	11.86%	-12.95%	-15.83%	-53.99%	-137.65%	16.36%
Free Cash Flow Firm Q/Q Growth	-127.26%	-5.23%	-80.10%	-338.11%	38.82%	22.75%	11.72%	-139.73%	-90.46%	9.07%
Invested Capital Q/Q Growth	46.63%	23.67%	33.56%	-7.51%	-16.76%	-32.03%	-50.78%	132.32%	-216.98%	66.09%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.01%	100.07%	100.00%	100.00%	100.00%	110.63%	100.19%	100.28%	100.14%	100.22%
Interest Burden Percent	102.04%	102.27%	107.75%	102.38%	102.84%	102.44%	101.70%	101.86%	101.61%	101.02%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-69.29%	-73.46%	-38.39%	-45.44%	-44.98%	-41.33%	-34.51%	-36.50%	-73.31%	-78.34%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,779.50%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-69.29%	-73.46%	-38.39%	-45.44%	-44.98%	-41.33%	-34.51%	-36.50%	-73.31%	-78.34%
Return on Equity Simple (ROE_SIMPLE)	-67.97%	0.00%	-23.62%	-26.84%	-30.85%	0.00%	-32.33%	-33.91%	-76.42%	0.00%
Net Operating Profit after Tax (NOPAT)	-19	-18	-20	-29	-28	-29	-40	-37	-106	-85
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.78%	-4.57%	-3.15%	-3.11%	-2.41%	-3.16%	-2.33%	-2.20%	-10.52%	-6.88%
Return On Investment Capital (ROIC_SIMPLE)	-	-10.32%	-	-	-	-5.14%	-	-	-	-19.56%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-26	-24	-27	-37	-34	-36	-51	-47	-147	-117
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-26	-24	-28	-38	-36	-37	-53	-49	-149	-119
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.48	3.90	1.78	3.12	2.84	1.58	2.13	1.53	2.07	2.07
Price to Tangible Book Value (P/TBV)	1.48	3.90	1.78	3.12	2.84	1.58	2.13	1.53	2.07	2.07
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	32.55	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.13	0.13	0.05	0.06	0.06	0.05	0.05	0.05	0.09	0.09
Long-Term Debt to Equity	0.08	0.13	0.05	0.06	0.06	0.05	0.05	0.04	0.09	0.09
Financial Leverage	-1.10	-1.08	-1.03	-1.10	-1.06	-1.05	-1.04	-1.00	-1.03	-1.02
Leverage Ratio	1.23	1.29	1.15	1.23	1.17	1.15	1.12	1.12	1.17	1.15
Compound Leverage Factor	1.26	1.32	1.24	1.26	1.21	1.18	1.14	1.14	1.18	1.16
Debt to Total Capital	11.40%	11.74%	5.18%	5.25%	5.67%	4.42%	4.66%	4.65%	8.59%	8.19%
Short-Term Debt to Total Capital	3.87%	0.00%	0.00%	0.00%	0.00%	0.00%	0.35%	0.88%	0.00%	0.00%
Long-Term Debt to Total Capital	7.53%	11.74%	5.18%	5.25%	5.67%	4.42%	4.31%	3.77%	8.59%	8.19%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	88.60%	88.26%	94.82%	94.75%	94.33%	95.58%	95.34%	95.35%	91.41%	91.81%
Debt to EBITDA	-0.19	-0.20	-0.24	-0.21	-0.20	-0.18	-0.15	-0.14	-0.12	-0.10
Net Debt to EBITDA	1.71	1.68	4.44	3.88	3.37	3.99	3.26	2.88	1.34	1.09
Long-Term Debt to EBITDA	-0.13	-0.20	-0.24	-0.21	-0.20	-0.18	-0.14	-0.12	-0.12	-0.10
Debt to NOPAT	-0.27	-0.28	-0.33	-0.28	-0.26	-0.23	-0.20	-0.19	-0.17	-0.13
Net Debt to NOPAT	2.41	2.35	6.17	5.26	4.47	5.23	4.27	3.78	1.83	1.50
Long-Term Debt to NOPAT	-0.18	-0.28	-0.33	-0.28	-0.26	-0.23	-0.18	-0.15	-0.17	-0.13
Altman Z-Score	1.36	6.30	9.83	16.19	13.63	8.32	9.37	6.54	3.74	4.28
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.81	7.97	20.56	18.96	18.23	20.04	15.03	13.92	11.66	13.19
Quick Ratio	5.62	7.64	20.02	18.42	17.78	19.55	14.70	12.76	10.83	12.18
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.93	-7.30	-13	-58	-35	-27	-24	-58	-110	-100
Operating Cash Flow to CapEx	0.00%	-1,354,800.00%	0.00%	0.00%	0.00%	-857,325.00%	0.00%	0.00%	0.00%	-810,533.33%
Free Cash Flow to Firm to Interest Expense	-12.96	-13.39	-6.33	-64.41	-36.73	-31.42	-27.84	-65.89	-46.44	-83.74
Operating Cash Flow to Interest Expense	-27.69	-49.72	-14.50	-38.53	-31.66	-39.60	-46.03	-69.98	-61.54	-102.08
Operating Cash Flow Less CapEx to Interest Expense	-27.69	-49.72	-14.50	-38.53	-31.66	-39.60	-46.03	-69.98	-61.54	-102.09
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-21	-16	-11	-12	-13	-18	-27	8.66	-10	-3.43
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-12	-10	-6.82	28	7.68	-1.63	-16	20	3.33	14
Enterprise Value (EV)	53	424	339	927	742	291	551	282	396	426
Market Capitalization	226	592	795	1,381	1,165	845	1,088	788	784	830
Book Value per Share	$3.90	$3.26	$8.54	$6.07	$5.43	$7.09	$5.46	$5.23	$3.57	$3.78
Tangible Book Value per Share	$3.90	$3.26	$8.54	$6.07	$5.43	$7.09	$5.46	$5.23	$3.57	$3.78
Total Capital	172	172	470	466	435	561	535	540	414	437
Total Debt	20	20	24	24	25	25	25	25	36	36
Total Long-Term Debt	13	20	24	24	25	25	23	20	36	36
Net Debt	-174	-168	-457	-454	-424	-554	-537	-506	-388	-404
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-21	-17	-11	-12	-14	-15	-24	12	-6.70	0.37
Debt-free Net Working Capital (DFNWC)	172	171	470	466	434	564	538	543	417	440
Net Working Capital (NWC)	165	171	470	466	434	564	537	538	417	440
Net Nonoperating Expense (NNE)	7.88	6.85	8.87	8.90	7.18	11	12	11	43	33
Net Nonoperating Obligations (NNO)	-174	-168	-457	-454	-424	-554	-537	-506	-388	-404
Total Depreciation and Amortization (D&A)	-0.22	-0.25	-0.81	-0.90	-1.86	-1.75	-2.65	-2.40	-2.30	-1.75
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.57)	$0.13	($0.54)	($0.52)	($0.45)	($0.49)	($0.54)	($0.48)	($1.39)	($1.10)
Adjusted Weighted Average Basic Shares Outstanding	47.25M	34.81M	53.17M	74.13M	76.34M	71.17M	95.85M	99.83M	107.08M	104.71M
Adjusted Diluted Earnings per Share	($0.57)	$0.13	($0.54)	($0.52)	($0.45)	($0.49)	($0.54)	($0.48)	($1.39)	($1.10)
Adjusted Weighted Average Diluted Shares Outstanding	47.25M	34.81M	53.17M	74.13M	76.34M	71.17M	95.85M	99.83M	107.08M	104.71M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.54M	52.23M	72.87M	75.48M	75.64M	93.50M	98.38M	105.91M	106.13M	145.98M
Normalized Net Operating Profit after Tax (NOPAT)	-19	-18	-20	-29	-28	-29	-40	-37	-106	-85
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-49.10	-44.11	-12.90	-41.95	-35.21	-41.00	-58.77	-53.73	-62.03	-98.16
NOPAT to Interest Expense	-35.38	-32.58	-9.62	-32.99	-28.72	-33.31	-46.46	-42.80	-45.03	-71.71
EBIT Less CapEx to Interest Expense	-49.10	-44.12	-12.90	-41.95	-35.21	-41.00	-58.77	-53.73	-62.03	-98.17
NOPAT Less CapEx to Interest Expense	-35.38	-32.58	-9.62	-32.99	-28.72	-33.31	-46.46	-42.80	-45.03	-71.72
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.07%

Frequently Asked Questions About 89bio's Financials

When does 89bio's financial year end?

According to the most recent income statement we have on file, 89bio's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has 89bio's net income changed over the last 2 years?

89bio's net income appears to be on an upward trend, with a most recent value of -$367.08 million in 2024, rising from -$102.03 million in 2022. The previous period was -$142.19 million in 2023.

What is 89bio's operating income?

89bio's total operating income in 2024 was -$384.66 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $384.66 million

How has 89bio revenue changed over the last 2 years?

Over the last 2 years, 89bio's total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does 89bio have?

89bio's total liabilities were at $77.90 million at the end of 2024, a 29.9% increase from 2023, and a 73.1% increase since 2022.

How much cash does 89bio have?

In the past 2 years, 89bio's cash and equivalents has ranged from $55.26 million in 2022 to $316.16 million in 2023, and is currently $126.06 million as of their latest financial filing in 2024.

How has 89bio's book value per share changed over the last 2 years?

Over the last 2 years, 89bio's book value per share changed from 3.26 in 2022 to 3.78 in 2024, a change of 15.8%.

Related Companies

This page (NASDAQ:ETNB) was last updated on 4/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

89bio (ETNB) Financials

Frequently Asked Questions About 89bio's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

89bio (ETNB) Financials

Annual Income Statements for 89bio

Quarterly Income Statements for 89bio

Annual Cash Flow Statements for 89bio

Quarterly Cash Flow Statements for 89bio

Annual Balance Sheets for 89bio

Quarterly Balance Sheets for 89bio

Annual Metrics and Ratios for 89bio

Quarterly Metrics and Ratios for 89bio

Frequently Asked Questions About 89bio's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools